Jennifer Steel1, Andrew Baum, Brian Carr. 1. University of Pittsburgh School of Medicine, Department of Surgery; Starzl Transplantation Institute; Liver Cancer Center, Pittsburgh, PA 15213, USA. steelj@msx.dept-med.pitt.edu
Abstract
BACKGROUND: The aims of the study were to test the difference in health-related quality (HRQL) of life and survival in patients diagnosed with primary hepatocellular carcionma (HCC) and treated with either hepatic arterial infusion (HAI) of Cisplatin or 90-Yttrium microspheres (Therasphere). METHOD: The design of the study was a non-randomized parallel cohort study. Twenty-eight patients participated in the present study. HRQL was assessed by administration of the Functional Assessment of Cancer Therapy-Hepatobiliary. Survival was measured using Kaplan Meier methods. RESULTS: The results of present study suggest treatment with Therasphere) had an advantage in regard to HRQL and survival when compared to Cisplatin. At 3-month follow-up, patients who were treated with Therasphere had a higher level of functional well-being as well as overall quality of life when compared to patients treated with Cisplatin. At 6-month follow-up patients (treated with Therasphere) continued to have better functional well-being when compared to patients being treated with HAI of Cisplatin. At 6-month follow-up, survival was found to be similar for patients treated with Therasphere when compared to patients being treated with Cisplatin. CONCLUSIONS: Preliminary data suggest that treatment with Therasphere has a modest advantage in regard to HRQL when compared patients treated with HAI of Cisplatin. Future research with Therasphere, that includes a larger sample size and longer follow-up, is necessary to make definitive conclusions regarding the efficacy and effect on HRQL. Copyright 2003 John Wiley & Sons, Ltd.
BACKGROUND: The aims of the study were to test the difference in health-related quality (HRQL) of life and survival in patients diagnosed with primary hepatocellular carcionma (HCC) and treated with either hepatic arterial infusion (HAI) of Cisplatin or 90-Yttrium microspheres (Therasphere). METHOD: The design of the study was a non-randomized parallel cohort study. Twenty-eight patients participated in the present study. HRQL was assessed by administration of the Functional Assessment of Cancer Therapy-Hepatobiliary. Survival was measured using Kaplan Meier methods. RESULTS: The results of present study suggest treatment with Therasphere) had an advantage in regard to HRQL and survival when compared to Cisplatin. At 3-month follow-up, patients who were treated with Therasphere had a higher level of functional well-being as well as overall quality of life when compared to patients treated with Cisplatin. At 6-month follow-up patients (treated with Therasphere) continued to have better functional well-being when compared to patients being treated with HAI of Cisplatin. At 6-month follow-up, survival was found to be similar for patients treated with Therasphere when compared to patients being treated with Cisplatin. CONCLUSIONS: Preliminary data suggest that treatment with Therasphere has a modest advantage in regard to HRQL when compared patients treated with HAI of Cisplatin. Future research with Therasphere, that includes a larger sample size and longer follow-up, is necessary to make definitive conclusions regarding the efficacy and effect on HRQL. Copyright 2003 John Wiley & Sons, Ltd.
Authors: P C Robson; N Heffernan; M Gonen; R Thornton; L A Brody; R Holmes; K T Brown; A M Covey; D Fleischer; G I Getrajdman; W Jarnagin; C Sofocleous; L Blumgart; M D'Angelica Journal: Ann Surg Oncol Date: 2010-04-01 Impact factor: 5.344
Authors: Tobias F Jakobs; Ralf-T Hoffmann; Gabriele Poepperl; Anna Schmitz; Jürgen Lutz; Walter Koch; Klaus Tatsch; Andreas Lubiensky; Maximilian F Reiser; Thomas Helmberger Journal: Eur Radiol Date: 2006-12-06 Impact factor: 5.315
Authors: Karen Kaiser; Rajiv Mallick; Zeeshan Butt; Mary F Mulcahy; Al B Benson; David Cella Journal: Support Care Cancer Date: 2013-11-21 Impact factor: 3.603
Authors: Louis Rivera; Huan Giap; William Miller; Jonathan Fisher; Donald J Hillebrand; Christopher Marsh; Randolph L Schaffer Journal: World J Gastroenterol Date: 2006-09-21 Impact factor: 5.742